Antibody Therapeutics Xchange - Boston 2026: Highlights and Event Recap

Antibody Therapeutics Xchange - Boston 2026 was held on April 28, 2026. The event brought together industry leaders from the pharmaceutical and biotech sectors to tackle key challenges in Target Selection & Mechanisms of Action, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multispecifics, ADC Linker Design & Conjugation Technologies, and ADC Cytotoxic Payload. 

Key Trends in Antibody Therapeutics

1. Integration of AI across discovery workflows: application of generative models, structural prediction, and developability screening early in lead identification to compress timelines and improve candidate quality.  

2. Shift toward multispecific and complex antibody formats: increase in bispecifics, VHH-based constructs, and synthetic immune synapse engineering to address limitations of monospecific antibodies.  

3. Increased focus on developability and manufacturability: parallel optimization of affinity, specificity, and biophysical properties during early discovery stages.  

4. Advances in ADC design: continued refinement of linker chemistry, conjugation strategies, and payload selection to balance efficacy and toxicity.  

5. Target biology-driven design: integration of spatial multiomics and tissue-level analysis to improve target selection and reduce on-target/off-tumor effects.  

1. Target Selection & Mechanisms of Action

• Minimizing on-target toxicity through target biology integration (Johnson & Johnson): Strategies to discriminate diseased versus healthy tissue expression and mitigate adverse effects via mechanism-of-action-informed design. 

• Parallel engineering for affinity, specificity, and developability with an emphasis on simultaneous optimization of multiple antibody properties to address differentiation and patentability challenges in increasingly crowded antibody landscapes. 

• Overcoming membrane protein complexity using display technologies (Modunai Therapeutics): Application of advanced display platforms to address tumor microenvironment (TME) biology and enable targeting of complex membrane protein assemblies. 

2. Lead Identification & Optimization

• Impact of delivery technologies on lead requirements (Merck): Manufacturing, formulation, and half-life extension technologies are redefining criteria for stability, dosing, and developability in antibody candidates. 

• AI-enabled early developability and affinity optimization through evaluation of optimal stages for AI integration, including affinity maturation and cross-reactivity prediction.  

• AI and structural biology integration for rational design (Alevian): Leveraging high-quality structural datasets to improve predictive modeling and reduce reliance on low-resolution or sparse data. 

3. Formats, Scaffolds & Multispecifics

• VH/VHH discovery and developability optimization (Ecliptic Bio): Comparison of transgenic mouse platforms, synthetic libraries, and llama immunization for binder diversity and drug-like properties. 

• Emerging multispecific therapeutic strategies (GV20 Therapeutics): Engineering cell-surface target degraders and recycling antibodies to enhance efficacy and pharmacokinetics. 

• Developability-driven biologics discovery through early incorporation of cell-based assays and developability metrics to improve downstream success rates.  

• Building block compatibility in multispecific design (Crossbow Therapeutics): Importance of domain selection, linker strategies, and aggregation risk mitigation in complex antibody architectures. 

• Synthetic immune synapse engineering (Imgen Biosciences): Design of next-generation T cell engagers to overcome limitations of endogenous immune recognition systems. 

4. ADC Linker Design & Conjugation Technologies

• Balancing linker stability and payload release (GSK): Optimization of linker chemistry to ensure systemic stability while enabling efficient intracellular cleavage. 

• Conjugation strategies to reduce off-target toxicity through control of drug-antibody ratio (DAR), linker kinetics, and structural features to improve ADC safety and efficacy.  

• Analytical and structural considerations in ADC design with an emphasis on analytical robustness and stoichiometry control to support consistent manufacturing and performance.  

5. ADC Cytotoxic Payloads & Resistance

• Mechanisms of resistance to ADC payloads (AstraZeneca): Identification of cellular pathways affecting intracellular trafficking, lysosomal release, and payload efficacy. 

• Use of biomarkers to stratify patients and guide therapeutic strategies targeting resistance mechanisms.  

• Development of safer, more potent cytotoxins (Regenova Pharmaceuticals): Optimization of payload-linker combinations to reduce systemic toxicity while maintaining antitumor activity. 

Thank you to everyone who met us at Antibody Therapeutics BOSTON Xchange 2026 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.